A longitudinal analysis of the effect of anemia on health-related quality of life in children with mild-to-moderate chronic kidney disease.


Journal

Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728

Informations de publication

Date de publication:
09 2020
Historique:
received: 13 12 2019
accepted: 03 04 2020
revised: 01 04 2020
pubmed: 26 4 2020
medline: 16 6 2021
entrez: 26 4 2020
Statut: ppublish

Résumé

To evaluate impact of anemia on health-related quality of life (HRQOL) over time in a large pediatric cohort with mild-to-moderate chronic kidney disease (CKD). Participants were enrolled in the Chronic Kidney Disease in Children Study (CKiD), a multicenter, longitudinal cohort. HRQOL was measured using the Pediatric Quality of Life Inventory (PedsQL). Anemia was defined as hemoglobin < 5th percentile for age, sex, and race. Two longitudinal analyses were conducted on consecutive visit pairs. Models examined effects of anemia status on both HRQOL score over time and change in HRQOL score between consecutive visits. The sample included 733 children with a median estimated GFR 54 ml/min/1.73 m Analysis of HRQOL scores revealed the presence of anemia was associated with significantly lower overall HRQOL (β = - 2.90 (95% CI = - 7.74, - 0.21), p = 0.04) and physical functioning (β = - 5.72 (- 9.49, - 2.25), p = 0.001) according to children. On parent ratings, the development of anemia was associated with lower emotional functioning scores (β = - 4.87 (- 8.72, - 0.11), p = 0.045). In the second model, children who developed anemia were rated by caregivers as having more decreased physical functioning than children who remained anemia-free (β = - 3.30 per year (- 5.83, - 0.76), p = 0.01). Caregivers did not observe declines in their children's other PedsQL subscales in the presence of developed anemia. Children with resolved or persistence did not show improvement or decline in any aspect of HRQOL functioning relative to non-anemic subjects. In children with CKD, anemia has an adverse effect on HRQOL which persists over time but does not appear to be progressive.

Sections du résumé

BACKGROUND
To evaluate impact of anemia on health-related quality of life (HRQOL) over time in a large pediatric cohort with mild-to-moderate chronic kidney disease (CKD).
METHODS
Participants were enrolled in the Chronic Kidney Disease in Children Study (CKiD), a multicenter, longitudinal cohort. HRQOL was measured using the Pediatric Quality of Life Inventory (PedsQL). Anemia was defined as hemoglobin < 5th percentile for age, sex, and race. Two longitudinal analyses were conducted on consecutive visit pairs. Models examined effects of anemia status on both HRQOL score over time and change in HRQOL score between consecutive visits. The sample included 733 children with a median estimated GFR 54 ml/min/1.73 m
RESULTS
Analysis of HRQOL scores revealed the presence of anemia was associated with significantly lower overall HRQOL (β = - 2.90 (95% CI = - 7.74, - 0.21), p = 0.04) and physical functioning (β = - 5.72 (- 9.49, - 2.25), p = 0.001) according to children. On parent ratings, the development of anemia was associated with lower emotional functioning scores (β = - 4.87 (- 8.72, - 0.11), p = 0.045). In the second model, children who developed anemia were rated by caregivers as having more decreased physical functioning than children who remained anemia-free (β = - 3.30 per year (- 5.83, - 0.76), p = 0.01). Caregivers did not observe declines in their children's other PedsQL subscales in the presence of developed anemia. Children with resolved or persistence did not show improvement or decline in any aspect of HRQOL functioning relative to non-anemic subjects.
CONCLUSIONS
In children with CKD, anemia has an adverse effect on HRQOL which persists over time but does not appear to be progressive.

Identifiants

pubmed: 32333284
doi: 10.1007/s00467-020-04569-5
pii: 10.1007/s00467-020-04569-5
pmc: PMC8958595
mid: NIHMS1786244
doi:

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1659-1667

Subventions

Organisme : NIDDK NIH HHS
ID : U01 DK066143
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK066174
Pays : United States
Organisme : NIDDK NIH HHS
ID : U24-DK-66116
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01-DK-66143
Pays : United States
Organisme : NIDDK NIH HHS
ID : U24 DK066116
Pays : United States
Organisme : NIDDK NIH HHS
ID : U24 DK082194
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01-Dk-66174
Pays : United States
Organisme : NIDDK NIH HHS
ID : U24-DK-082194
Pays : United States

Références

Clin J Am Soc Nephrol. 2006 Sep;1(5):1006-15
pubmed: 17699320
Am J Kidney Dis. 2015 Dec;66(6):984-92
pubmed: 26209544
Pediatr Nephrol. 2009 Aug;24(8):1553-60
pubmed: 19421787
Am J Kidney Dis. 2004 Dec;44(6):1017-23
pubmed: 15558522
Arq Gastroenterol. 2015 Dec;52(4):255-9
pubmed: 26840464
Ann Intern Med. 2016 Apr 5;164(7):472-8
pubmed: 26881842
Pharmacoecon Open. 2019 Dec;3(4):463-478
pubmed: 30968369
Kidney Int. 2012 Aug;82(4):445-53
pubmed: 22622496
Pediatrics. 2010 Feb;125(2):e349-57
pubmed: 20083528
J Nephrol. 2006 Sep-Oct;19(5):640-7
pubmed: 17136694
Am J Kidney Dis. 2013 Dec;62(6):1087-94
pubmed: 23932090
N Engl J Med. 2006 Nov 16;355(20):2085-98
pubmed: 17108343
Clin Nephrol. 2011 Jun;75(6):524-33
pubmed: 21612756
Am J Kidney Dis. 1991 Oct;18(4 Suppl 1):62-70
pubmed: 1928082
Health Qual Life Outcomes. 2007 Jul 16;5:43
pubmed: 17634123
Pediatr Nephrol. 2012 Dec;27(12):2293-300
pubmed: 22832667
Pediatr Nephrol. 2020 Jul;35(7):1287-1295
pubmed: 32157444
Cancer Manag Res. 2016 Jan 21;8:1-10
pubmed: 26855598
Health Qual Life Outcomes. 2016 Jun 24;14:94
pubmed: 27342630
BMC Nephrol. 2016 Jul 26;17(1):97
pubmed: 27460779
Adv Ther. 2017 Jul;34(7):1662-1672
pubmed: 28578500
Pediatr Nephrol. 2017 Nov;32(11):2097-2105
pubmed: 28685173
Ambul Pediatr. 2003 Nov-Dec;3(6):329-41
pubmed: 14616041
Pediatr Nephrol. 2018 Feb;33(2):227-238
pubmed: 28412770
Clin Ther. 2003 Jun;25(6):1786-805
pubmed: 12860499
J Pediatr. 2013 Sep;163(3):736-41.e1
pubmed: 23628375
N Engl J Med. 2006 Nov 16;355(20):2071-84
pubmed: 17108342

Auteurs

Joann Carlson (J)

Division of Pediatric Nephrology and Hypertension, Department of Pediatrics, Rutgers/Robert Wood Johnson Medical School, New Brunswick, NJ, USA. Joann.Carlson@rutgers.edu.

Arlene C Gerson (AC)

Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Matthew B Matheson (MB)

Department of Epidemiology, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Sharon Manne (S)

Department of Medicine, Rutgers/Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

Bradley A Warady (BA)

Division of Pediatric Nephrology, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, MO, USA.

Stephen R Hooper (SR)

Department of Allied Health Sciences, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Marc Lande (M)

Department of Pediatrics, University of Rochester Medical Center, Rochester, NY, USA.

Lyndsay A Harshman (LA)

Division of Pediatric Nephrology, University of Iowa Stead Family Department of Pediatrics, University of Iowa, Iowa City, IA, USA.

Rebecca J Johnson (RJ)

Division of Developmental and Behavioral Health, Department of Pediatrics, Children's Mercy Kansas City, UMKC School of Medicine, Kansas City, MO, USA.

Shlomo Shinnar (S)

Department of Neurology, Pediatrics and Epidemiology and Population Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.

Amy J Kogon (AJ)

Children's Hospital of Philadelphia, Division of Pediatric Nephrology, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Susan Furth (S)

Children's Hospital of Philadelphia, Division of Pediatric Nephrology, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH